Adult Atopic Dermatitis Clinical Trial
Official title:
Evaluation of the Effects of a Combination of Probiotics in the Treatment of Adult Atopic Dermatitis: Randomized Phase III, Double-blind Placebo-controlled
| Verified date | January 2012 |
| Source | Ospedale L. Sacco – Polo Universitario |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Italy: Ministry of Health |
| Study type | Interventional |
Probiotics are suggested to have beneficial effects in atopic dermatitis (AD) treatment and
prevention but their precise role is not yet clear.
The aim of this randomized double blinded active treatment vs placebo study was to evaluate
clinical efficacy of intake of a combination of two probiotics (Lactobacillus salivarius
LS01 and Bifidobacterium breve BR03) for the treatment of adult AD patients.
The rationale for the use of probiotics in the treatment of atopic dermatitis would be due
to some experimental hypotheses:
1. The use of these microbial agents at an early age seems to play an important role in
inducing immunity T type 1 (Th1) and inhibit the development of a Th2 response IgE
mediated
2. the normal intestinal flora (including probiotics) would play an important role in
inducing immunological tolerance
3. the hygiene hypothesis that the reduced bacterial environment would favour a type 2
response T and the development of allergic diseases
| Status | Completed |
| Enrollment | 48 |
| Est. completion date | September 2010 |
| Est. primary completion date | September 2010 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 55 Years |
| Eligibility |
Inclusion Criteria:Adults aged 18-55 years between - Diagnosis of DA moderate and / or severe, as assessed by the use of a standardized index of severity of AD (SCORAD = Scoring Atopic Dermatitis index) (42), prepared by the European Task Force for atopic dermatitis Exclusion Criteria:Allergic contact dermatitis (ACD), active - In the absence of known food allergy elimination diet - Chronic diseases (autoimmune diseases, COPD, heart disease, IRC, CNS disease, chronic gastrointestinal diseases, diabetes, congenital or acquired immunosuppression) - Pregnancy and / or lactation - Treatment with probiotics in the 6 months preceding enrollment - Treatment with steroids and antihistamines systemically in the three months prior to enrollment - Topical treatments with immunomodulators (tacrolimus or pimecrolimus) in the three months prior to enrollment - Acute or chronic infectious diseases - Pre-existing hypersensitivity to components contained in the probiotic |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Italy | Luigi Sacco Hospital | Milano |
| Lead Sponsor | Collaborator |
|---|---|
| Ospedale L. Sacco – Polo Universitario |
Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | clinical effects of probiotics on adult atopic dermatitis | To evaluate the clinical course of adult patients affected by atopic dermatitis after the intake of two probiotics vs placebo | 20 weeks | Yes |
| Secondary | effects of probiotics on immune system and faecal microbiota in adult atopic dermatitis | to evaluate these parameters: percentage of circulating Treg cells, percentage of Th17 cells, Th1 and Th2, percentage of Treg cells TLR2+, TLR4 + and TLR9 +, Quantization plasma LPS. Determination by gene amplification and culture of Lactobacillus salivarius and Bifidobacterium in the faeces of the two groups studied | 20 weeks | No |